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Rational modification of an HIV-1 gp120 results in
enhanced neutralization breadth when used as a
DNA prime
A Wallace*, MJ Duenas-Decamp, M Vaine, PJ Peters, S Wang, PR Clapham, S Lu
From AIDS Vaccine 2012
Boston, MA, USA. 9-12 September 2012
Background
The identification of phenotypic features of the HIV-1
envelope glycoprotein that correlate with neutralization
breadth is an important goal of HIV vaccine research.
Recently we compared the immunogenic potential of two
gp120s differing in their ability to utilize CD4; B33
(highly macrophage topic) and LN40 (non-macrophage
tropic). Using a DNA prime protein boost regimen in
New Zealand White Rabbits, LN40-primed sera displayed
enhanced breadth compared to the B33-primed group,
with differences in immunogenicity between groups
modulated by specific residues within and flanking the
V3 loop and the CD4bs. To better understand the role of
these residues in eliciting breadth, we introduced recipro-
cal mutations between LN40 and B33 at these critical
positions.
Methods
Three groups of four rabbits were primed with one of
three chimeric LN40/B33 gp120 DNAs, followed by a
polyvalent protein boost. Time course and endpoint titers
were determined via ELISA. Neutralization breadth was
analyzed by Monogram against a panel of sixteen viruses
using a Phenosense neutralization assay. Anti-gp120
serum specificities were determined using a set of over-
lapping peptides spanning the entire gp120 via ELISA.
Results
We found that sera primed with a B33 chimera containing
specific LN40 residues within the V3 loop and the CD4
binding loop displayed enhanced neutralization breadth
against a cross-clade panel of Tier 1 and 2 viruses com-
pared to the B33-primed group. Interestingly, a second
B33 chimera containing two additional LN40 substitutions
(Stu-Bsu R373/N386) within C3/V4 primed the broadest
response, being broader than even the LN40-primed
group. Additionally, peptide ELISAs showed differences in
reactivity between priming groups which were most pro-
nounced for the C3/V4 region, suggesting an important
role for these regions in modulating serum antibody
responses against gp120.
Conclusion
While the role of R373/N386 is still under investigation,
these results represent potentially promising steps towards
the rational, targeted design of a better gp120 immunogen.
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